Acta parasitologica · 2026
Integrated Experimental and Computational Investigation of Azobenzenoid Derivatives Against Trypanosomatid: RNA Editing Ligase 1 as a Potential Molecular Target.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khan Asif, Balbinot Rodolfo Bento, Lazarin-Bidóia Danielle, Paetzold Maira Gabriela, Seixas Íris Nunes, Ramos Silva Gustavo Nunes, Fernandez Maria Aparecida, Nakamura Celso Vataru, Seixas Flavio Augusto Vicente
Аннотация
BACKGROUND: Neglected tropical diseases caused by pathogenic protozoa, including Chagas Disease (etiological agent Trypanosoma cruzi) and leishmaniasis (etiological agent Leishmania spp.), are public health problems in many developing countries.
AIMS AND METHODOLGY: Due to the lack of safe and effective therapies, the current study was designed to screen synthetic azobenzenoid derivatives using integrated in silico and in vitro assays.
RESULTS: Among the tested compounds, CaCS2 potentially inhibited promastigotes and amastigotes of Leishmania amazonensis and epimastigotes and trypomastigotes of Trypanosoma cruzi, while showing no cytotoxicity towards human J774A.1 and LLC-MK2 cell lines. Reverse docking identified the parasite-specific RNA-editing ligase 1 (REL1), completely absent in humans, as a high-confidence target (p-value = 1.76 × 10-12; MaxTC = 0.31). Similarly, docking simulations revealed high binding probabilities for CaCS2 in two main cavities of REL1, named the orthosteric and alternative sites, in both parasites. Molecular dynamic simulations confirmed stable CaCS2 binding at the orthosteric site, while interactions at the alternative site were transient.
CONCLUSION: Interestingly, CaCS2 was a specific ligand to REL1 and non cytotoxic to human cell lines, making it a promising scaffold for anti-trypanosomatid development.
AIMS AND METHODOLGY: Due to the lack of safe and effective therapies, the current study was designed to screen synthetic azobenzenoid derivatives using integrated in silico and in vitro assays.
RESULTS: Among the tested compounds, CaCS2 potentially inhibited promastigotes and amastigotes of Leishmania amazonensis and epimastigotes and trypomastigotes of Trypanosoma cruzi, while showing no cytotoxicity towards human J774A.1 and LLC-MK2 cell lines. Reverse docking identified the parasite-specific RNA-editing ligase 1 (REL1), completely absent in humans, as a high-confidence target (p-value = 1.76 × 10-12; MaxTC = 0.31). Similarly, docking simulations revealed high binding probabilities for CaCS2 in two main cavities of REL1, named the orthosteric and alternative sites, in both parasites. Molecular dynamic simulations confirmed stable CaCS2 binding at the orthosteric site, while interactions at the alternative site were transient.
CONCLUSION: Interestingly, CaCS2 was a specific ligand to REL1 and non cytotoxic to human cell lines, making it a promising scaffold for anti-trypanosomatid development.